Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
SS-31 vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Both have FDA-approved products for defined, product-specific indications.
⇄ Different
Biggest Difference
SS-31 is distinguished by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
SS-31 is distinguished in the current record by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
SS-31: Mixed human evidence. Tirzepatide: Mature human evidence.
Regulatory historyComparable
SS-31: Narrow FDA accelerated approval. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
SS-31
- Barth syndrome
- Primary mitochondrial myopathy
- Dry age-related macular degeneration
- Heart failure
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
SS-31Narrow accelerated approval
FDA accelerated approval as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Other uses remain unapproved.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
SS-31Mixed controlled trials
A very small Barth program, a negative 218-participant Phase 3 primary-mitochondrial-myopathy trial, negative primary outcomes in Phase 2 heart-failure and dry-AMD trials, and recruiting confirmatory programs.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
SS-31No dedicated benefit
No controlled human weight-management or body-composition benefit has been established.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
SS-31No approved indication
No FDA-approved diabetes indication or completed controlled diabetes-outcome program was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
SS-31No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
SS-31Negative Phase 2 primary outcome
The 71-participant PROGRESS-HF trial did not improve left-ventricular end-systolic volume or ejection fraction over four weeks. Barth cardiac observations come from a tiny uncontrolled extension.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
SS-31FORZINITY label only
FORZINITY has product-specific FDA labeling as a ready-to-use once-daily subcutaneous solution. That label does not establish dosing, reconstitution, compatibility, or storage for powdered or unverified SS-31 materials.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether the intermediate strength endpoint predicts meaningful functional benefit, plus long-term safety and efficacy outside Barth syndrome.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
SS-31
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.